Cytogen, Inc. (KOSDAQ:217330)

Market Cap	92.51B +18.3%
Revenue (ttm)	26.84B +70.8%
Net Income	-11.18B
EPS	-484.91
Shares Out	23.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	73,909
Open	4,145.00
Previous Close	4,025.00
Day's Range	3,915.00 - 4,190.00
52-Week Range	2,260.00 - 11,200.00
Beta	0.16
Analysts	n/a
Price Target	n/a
Earnings Date	May 29, 2026

About Cytogen

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is head...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 217330

Financial Performance

In 2025, Cytogen's revenue was 26.05 billion, an increase of 138.80% compared to the previous year's 10.91 billion. Losses were -12.34 billion, -27.89% less than in 2024.